Who Paid My Doc
John Spertus
Cardiovascular Disease Kansas City, MO Medical Doctor
NPI 1982603973 CMS profile 225339
4320 Wornall Rd, Suite 65, Kansas City, MO 64111
General payments
$360,209
Research payments
$4,200
Ownership & investment interest
$0
Research they led as principal investigator
$1,978,046
Through program year 2025, John Spertus of Kansas City, MO is reported in the CMS Open Payments database as having received $360,209 across 142 general payments and $4,200 in research payments paid to them. Separately, studies naming them as principal investigator received $1,978,046 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $166 | 2 | |
| 2024 | General | $163 | 1 | |
| 2023 | General | $105,059 | 32 | |
| 2023 | Research | $4,200 | 1 | |
| 2022 | General | $88,992 | 40 | |
| 2021 | General | $38,720 | 19 | |
| 2020 | General | $91,219 | 31 | |
| 2019 | General | $35,889 | 17 |
Beside peers
- John Spertus
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to John Spertus were reported at $166. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | John Spertus | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $35,889 | $450 | $127–$1,392 | $163 |
| 2020 | $91,219 | $242 | $77–$751 | $114 |
| 2021 | $38,720 | $335 | $101–$1,037 | $132 |
| 2022 | $88,992 | $395 | $121–$1,211 | $149 |
| 2023 | $105,059 | $443 | $136–$1,283 | $160 |
| 2024 | $163 | $450 | $136–$1,323 | $164 |
| 2025 | $166 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
143 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Missouri
Mikhail Kosiborod
Cardiovascular Disease · Kansas City, MO
Georges Chahoud
Cardiovascular Disease · Saint Louis, MO
William Bowen
Cardiovascular Disease · Saint Louis, MO
Daniel Kelly
Cardiovascular Disease · Saint Louis, MO
James Fairlamb
Cardiovascular Disease · Columbia, MO
James Ellison
Cardiovascular Disease · Chesterfield, MO
Related records
Cardiovascular Disease in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.